A Randomized, Double-Blind, Placebo-Controlled Study Using a Bayesian Adaptive Design to Evaluate the Efficacy and Safety of ABT-089 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study Using a Bayesian Adaptive Design to Evaluate the Efficacy and Safety of ABT-089 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2016

At a glance

  • Drugs Pozanicline (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 05 Jun 2009 Planned number of patients changed from 400 to 337 as reported by ClinicalTrials.gov.
    • 05 Jun 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 17 Dec 2007 Status changed from initiated to recruiting according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top